Brachyury: Strategies for Drugging an Intractable Cancer Therapeutic Target

Dang, 2017, Drugging the “undruggable” cancer targets, Nat. Rev. Cancer, 17, 502, 10.1038/nrc.2017.36 Vujovic, 2006, Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas, J. Pathol., 209, 157, 10.1002/path.1969 Roselli, 2012, Brachyury, a driver of the epithelial–mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer, Clin. Cancer Res., 18, 3868, 10.1158/1078-0432.CCR-11-3211 Jezkova, 2016, Brachyury identifies a class of enteroendocrine cells in normal human intestinal crypts and colorectal cancer, Oncotarget, 7, 11478, 10.18632/oncotarget.7202 Presneau, 2011, Role of the transcription factor T (Brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study, J. Pathol., 223, 327, 10.1002/path.2816 Shah, 2017, Brachyury–YAP regulatory axis drives stemness and growth in cancer, Cell Rep., 21, 495, 10.1016/j.celrep.2017.09.057 Sharifnia, 2019, Small-molecule targeting of brachyury transcription factor addiction in chordoma, Nat. Med., 25, 292, 10.1038/s41591-018-0312-3 Magnaghi, 2018, Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and Brachyury, Mol. Cancer Ther., 17, 603, 10.1158/1535-7163.MCT-17-0324 Cottone, 2018, A compound screen reveals potential novel therapeutic targets for chordoma: metabolic stress response and epigenetic control of brachyury, Cancer Res., 78, 1949, 10.1158/1538-7445.AM2018-1949 Newman, 2017, Crystal structure of human Brachyury (T) in complex with DNA, RCSB Protein Data Bank Sarkar, 2012, BRACHYURY confers cancer stem cell characteristics on colorectal cancer cells, Int. J. Cancer, 130, 328, 10.1002/ijc.26029 Heery, 2015, Phase I trial of a yeast-based therapeutic cancer vaccine (GI-6301) targeting the transcription factor Brachyury, Cancer Immunol. Res., 3, 1248, 10.1158/2326-6066.CIR-15-0119